Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Woman and Man Max 99 years
Astellas Pharma Global Development
Update Il y a 4 ans
A two-year, open-label clinical study of ASP015K in patients with moderate to severe rheumatoid arthritis (RA) who completed a previous study of ASP015K
The primary objective of this study is to evaluate the long-term safety and efficacy of ASP015K in subjects with Rheumatoid Arthritis (RA) who have completed a preceding ASP015K RA study
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED POST-TRANSPLANT) AND MMF WITH OR WITHOUT A MONOCLONAL ANTI-IL2R ANTIBODY (BASILIXIMAB)
The primary objective of this study is to compare the three therapy regimens with regard to renal function.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma US, Inc
Update Il y a 4 ans
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients Estudio fase II, randomizado, doble ciego, controlado con placebo, de escalonamiento de dosis para evaluar la seguridad y los efectos de Conivaptan intravenoso sobre la respuesta hemodinámica hepática en pacientes cirróticos euvolémicos o hipervolémicos estables
The objectives of this study are to evaluate the safety of two different doses of IV conivaptan (YM087 or Vaprisol®) in stable euvolemic or hypervolemic cirrhotic patients with serum sodium 115 – 140 ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
Studying the safe and effective use of Modigraf (a tacrolimus-containing medicine in the form of granules that can be suspended in fluid) to prevent rejection of transplants in children
F506-CL-0404A: To monitor the safety and efficacy of Modigraf® (tacrolimus granules) in stable paediatric allograft recipients. F506-CL-0404B: To monitor dose changes and tacrolimus whole blood tro...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINATION WITH STEROIDS IN PATIENTS UNDERGOING PRIMARY LIVER TRANSPLANTATION
To evaluate and to compare efficacy and safety of a dual regimen with oral modified release tacrolimus FK506E (MR4) / steroids versus a dual regimen with oral tacrolimus FK506 / steroids in patients u...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Étude 8951-CL-0103 : étude de phase 2 évaluant l’efficacité de l’IMAB362 en monothérapie ou en association avec le mFOLFOX6 (5-fluorouracile, leucovorine et oxaliplatine) chez des patients ayant un adénocarcinome de l’estomac ou de la jonction gastro-oesophagienne métastatique ou localement avancé et non résécable.
Le cancer de l’estomac prend habituellement naissance dans le revêtement interne de la paroi gastrique (appelé muqueuse). Avec environ 9 000 nouveaux cas par an, le cancer de l'estomac se situe au cin...
Country
France
organs
Estomac
,
Oesophage
,
Cardia (jonction gastro-œsophagienne)
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A study to investigate how effective and safe the study medication ‘mirabegron’ is and how long it stays in the body in children and adolescents aged 3 to less than 18 years with symptoms of an overactive bladder with a neurologic cause
To evaluate the efficacy of mirabegron after multiple-dose administration in the pediatric population.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc (APGD)
Update Il y a 4 ans
A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Determine the efficacy superiority of ASP2215 and/or ASP2215 plus azacitidine versus azacitidine as measured by overall survival (OS).
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Astellas Pharma US, Inc
Update Il y a 4 ans
A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
The primary objective of this study is to evaluate the urodynamic variables of male subjects with LUTS and BOO treated with the co-administration of 6 mg solifenacin succinate and TOCAS, and 9 mg soli...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes
• To evaluate the safety and tolerability of different doses and dose regimens of YM150 on top of standard treatment with Acetyl Salicylic Acid (ASA) with or without clopidogrel in the secondary preve...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next